Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

Company Overview

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron's marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder. The company also commercializes Dupixent and Kevzara in collaboration with Sanofi. Regeneron maintains additional investigational programs across oncology, immunology, neurology and other therapeutic areas.

Founded in 1988 and headquartered in Tarrytown, New York, Regeneron serves patients and healthcare providers in the United States and international markets. Its products are distributed globally through direct commercial operations and collaborations with other pharmaceutical companies. Leonard S. Schleifer is the company's co-founder, president and chief executive officer, while George D. Yancopoulos, also a co-founder, serves as president and chief scientific officer.

Key Stats

• Today's Range: $796.73 to $808.63
• 50-Day Range: $649.81 to $852.03
• 52-Week Range: $541.00 to $859.34
• Volume: 567,514 shs
• Average Volume: 606,166 shs
• Market Capitalization: $83.16 billion
• P/E Ratio: 19.96
• Dividend Yield: 0.47%
• Price Target: $800.36
• Consensus Rating: Moderate Buy

Regeneron Pharmaceuticals Stock Analysis - MarketRank™

Regeneron Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat, and ranked 115th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Regeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 14 buy ratings, 10 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Regeneron Pharmaceuticals is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Regeneron Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 14.19%

Earnings Growth

Earnings for Regeneron Pharmaceuticals are expected to grow by 14.19% in the coming year, from $44.25 to $50.53 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Regeneron Pharmaceuticals is 19.96, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.80.

Price to Earnings Ratio vs. Sector

The P/E ratio of Regeneron Pharmaceuticals is 19.96, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.78.

Price to Earnings Growth Ratio

Regeneron Pharmaceuticals has a PEG Ratio of 1.59. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Regeneron Pharmaceuticals has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.50% of the float of Regeneron Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Regeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3.15, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Regeneron Pharmaceuticals has recently decreased by 29.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Regeneron Pharmaceuticals has a dividend yield of 0.46%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Regeneron Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Regeneron Pharmaceuticals is 9.29%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Regeneron Pharmaceuticals will have a dividend payout ratio of 7.44% next year. This indicates that Regeneron Pharmaceuticals will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.47

News Sentiment

Regeneron Pharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 47 news articles for Regeneron Pharmaceuticals this week, compared to 10 articles on an average week.

Search Interest

12 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

16 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 433% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,432,488.00 in company stock.

Percentage Held by Insiders

6.97% of the stock of Regeneron Pharmaceuticals is held by insiders.

Percentage Held by Institutions

83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Record date for 8/31 Dividend: 8/18/2026
• Ex-Dividend for 8/31 Dividend: 8/18/2026
• Dividend Payable: 8/31/2026
• Today: 9/09/2026
• Wells Fargo 21st Annual Healthcare Conference: 9/09/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/14/2026
• Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum: 9/23/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:REGN
• CIK: 872589
• Web: www.regeneron.com
• Phone: (914) 847-7000
• Fax: 914-347-2113
• Employees: 15,410
• Year Founded: 1988

Price Target and Rating

• Average Price Target for Regeneron Pharmaceuticals: $800.36
• High Price Target: $1,030.00
• Low Price Target: $185.00
• Potential Upside/Downside: -0.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $40.46
• Trailing P/E Ratio: 19.96
• Forward P/E Ratio: 18.25
• P/E Growth: 1.59
• Net Income: $4.50 billion
• Net Margins: 27.86%
• Pretax Margin: 33.26%
• Return on Equity: 13.47%
• Return on Assets: 10.34%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 3.34
• Quick Ratio: 2.78

Sales & Book Value

• Annual Sales: $14.34 billion
• Price / Sales: 5.80
• Cash Flow: $41.85 per share
• Price / Cash Flow: 19.30
• Book Value: $295.66 per share
• Price / Book: 2.73

Miscellaneous

• Outstanding Shares: 102,960,000
• Free Float: 95,779,000
• Market Cap: $83.16 billion
• Optionable: Optionable
• Beta: 0.20